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Abstract
Background: Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spreads rapidly and has a high 
case-mortality rate. The nucleocapsid protein (NP) of SARS-CoV may be critical for pathogenicity. This study sought to 
discover the host proteins that interact with SARS-CoV NP.
Results: Using surface plasmon resonance biomolecular interaction analysis (SPR/BIA) and matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF) mass spectrometry, we found that only the proteasome subunit p42 
from human fetal lung diploid fibroblast (2BS) cells bound to SARS-CoV NP. This interaction was confirmed by the 
glutathione S-transferase (GST) fusion protein pulldown technique. The co-localization signal of SARS-CoV NP and 
proteasome subunit p42 in 2BS cells was detected using indirect immunofluorescence and confocal microscopy. p42 is 
a subunit of the 26S proteasome; this large, multi-protein complex is a component of the ubiquitin-proteasome 
pathway, which is involved in a variety of basic cellular processes and inflammatory responses.
Conclusion: To our knowledge, this is the first report that SARS-CoV NP interacts with the proteasome subunit p42 
within host cells. These data enhance our understanding of the molecular mechanisms of SARS-CoV pathogenicity and 
the means by which SARS-CoV interacts with host cells.
Background
The outbreak of severe acute respiratory syndrome
(SARS), which began in the Guangdong Province of
China, spread rapidly to more than 30 countries during
2003. SARS has an acute onset, is highly transmissible
and has a high case-mortality rate (approximately 10%)
[1,2]. During SARS infection, three phases of viral repli-
cation result in respiratory tract pathological changes and
an over-exuberant host immune response. This mediates
immunopathological damage of the lungs and other
organs, and pulmonary fibrosis. SARS mortality is caused
primarily by extensive lung damage and severe lym-
phopenia [3]. Approximately 10% of individuals (6.8% of
patients younger and 55% of patients older than 60 years
of age) with clinical symptoms died as a consequence of
immunopathological lung damage, caused by a hyperac-
tive antiviral immune response [4].
The mechanism of the serious damage to the respira-
t o ry  s y s t e m  c a u s e d  b y  S A R S- C o V  r e m a i n s  u n c l e a r .  A t
least two possibilities exist: (i) direct damage to cells and
tissues by the SARS-CoV and (ii) indirect damage, medi-
ated primarily by the cellular immune response and
cytokines.
SARS-CoV nucleocapsid protein (SARS-CoV NP) is an
extensively phosphorylated, highly basic, vital structural
protein the primary function of which is to form a helical
ribonucleoprotein complex with viral RNA (vRNA). This
complex comprises the core structure of the SARS-CoV
virion. A variety of functions have been ascribed to
SARS-CoV NP, including packaging, transcription, and
replication. However, these are based solely on known
functions of the NP of other coronaviruses [5]. SARS-
CoV NP shows intrinsic multimerization and interacts
with M protein, suggesting that NP is both critical to for-
mation of the viral nucleocapsid core and is involved in
virion assembly [6,7].
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Sequence analysis indicates that the RNA-binding
domain of SARS-CoV NP may be located at residues 178-
205 [8]. Motif scanning predicted a bipartite nuclear
localization signal, located at residues 373-390, suggest-
ing that this protein may play a role in the pathogenicity
of SARS-CoV [9].
SARS-CoV NP is highly immunogenic. Antibodies
against the nucleocapsid protein are longer lived and
occur in greater abundance in SARS patients than anti-
bodies against other viral components such as the spike,
membrane and envelope proteins [10]. This may be due
to the presence of higher levels of nucleocapsid protein,
compared with other viral proteins, after SARS-CoV
infection [11]. These data suggest that the SARS-CoV NP
is strongly antigenic and so may play an important role in
generation of the host immune response and immunop-
athological damage.
In this study, SPR/BIACORE, MALID-TOF MS, the
GST-fusion expression pulldown technique, and cell co-
localization were used to investigate the interactions of
SARS-CoV NP with host cell proteins. In this way, we
sought to further elucidate the molecular pathogenic
mechanisms of SARS-CoV. This, in turn, will allow devel-
opment of novel therapeutics effective against this debili-
tating infection.
Materials and methods
Plasmids and bacterial strains
Plasmid pET22b-SNP22b was constructed by cloning the
SARS-CoV NP (SNP22b) gene by reverse transcriptase
PCR (RT-PCR) using vRNA from SARS-CoV SCV-8 (iso-
lated from a SARS patient in Beijing, China) with the fol-
lowing primers: forward: 5'-GAAGGATCCGATGT
CTGATAATGGACCCCAATCAA-3', reverse: 5'-GCTG
AATTCTTAATGGTGATGGTGATGGTGTGCCTGA
GTTGAATCAGCAGAAGC-3'. PCR products were puri-
fied and inserted into the pET22b plasmid using BamHI/
EcoRI. The p42 gene was amplified by RT-PCR using
mRNA from 2BS cells with the following primers: p42
forward: 5'-GATGAATTCATGGCGGACCCTAGAGA-
TAAGG-3', reverse: 5'-GATCTCGAGTTACACAG-
GTTTGTAGTCCAATTTAG-3'. PCR products were
purified and cloned into the pGEX-5X-1 plasmid (Phar-
macia, GE) using XhoI/EcoRI, to generate pGEX-5X-1-
p42. The plasmid pcDNA3.0-SNP22b was constructed by
subcloning the SNP gene, released from pET22b-SNP22b
by BamHI/EcoRI, into pcDNA3.0 (Invitrogen). All of the
recombinant clones were confirmed by sequencing.
Escherichia coli DH5α and BL21 (DE3) were obtained
from Invitrogen (USA).
Cell culture, transfection, and reagents
Human fetal lung diploid fibroblast (2BS) cells (SARS-
CoV susceptible), were obtained from ATCC (USA) and
maintained in DMEM (Invitrogen), containing 10% fetal
bovine serum (FBS) and gentamicin (5 μg/mL). Transfec-
tion of 2BS cells was carried out using Lipofectamine
2000 according to the manufacturer's protocol. All
restriction endonucleases were purchased from New
England Biolabs (UK). Horse anti-SARS-CoV NP poly-
clonal antibody was a gift from the Academy of Military
Medical Sciences. The anti-SARS-CoV NP mAb was pre-
pared in our laboratory, while goat anti-mouse HRP-IgG
and goat anti-rabbit IgG-FITC conjugates were pur-
chased from Sigma (USA).
ELISA assay
Microtiter plates were coated with anti-SARS-CoV NP
mAb (5 μg/mL) in bicarbonate buffer (15 mM Na2CO3,
35 mM NaHCO3, pH 9.6) overnight at 4°C. Plates were
washed with PBST (100 mM NaCl, 10 mM Na2HPO4, 3
mM KH2PO4, 0.05% (v/v) Tween 20, pH 7.2) and blocked
using 5% (w/v) fat-free milk in PBST for 1 h at 37°C.
Plates were then washed with PBST and increasing con-
centrations of SARS-CoV NP added. SARS-CoV NP,
bovine serum albumin (BSA), and PBS were the positive,
negative, and blank controls, respectively. All plates were
then incubated at 37°C for 1 h, followed by washing six
times with PBST. All wells were incubated with anti-
SARS-CoV NP horse polyclonal antibody-HRP conjugate
for 1 h at 37°C. Plates were subsequently washed six times
with PBST; TMB chromogenic substrate solution and
stop solution were then added and the A450 was deter-
mined.
Immunoblot analysis
Samples were lysed in 1× loading buffer (0.08 M Tris,
2.0% (w/v) SDS, 10% (v/v) glycerol, 0.1 M dithiothreitol,
0.2% (w/v) bromophenol blue, pH 6.8). Samples were
boiled for 10 min and resolved by one-dimensional SDS-
PAGE. Proteins were transferred onto nitrocellulose
membranes and the membranes were probed with the
appropriate primary antibody. Secondary antibodies were
alkaline phosphatase-conjugated anti-human, anti-rabbit,
anti-mouse, or anti-goat IgG (Jackson Immunoresearch,
Inc.). Gels were stained using 5-bromo-4-chloro-3-indo-
lyl phosphate (BCIP) and nitro blue tetrazolium (NBT)
solutions (Sigma).
Expression, identification, and purification of recombinant 
SARS-CoV NP
Plasmid pET22b-SNP22b was transformed into E.  coli
BL21. The fusion protein SNP-His was expressed under 1
mM IPTG at 22°C for 12 h. Bacteria were harvested and
lyzed in lysis buffer (1 mg/mL lysozyme (Sigma), 1% (v/v)
Triton X-100, 5 μg/mL DNAse, 5 μg/mL RNAse) at 4°C
for 30 min. Lysates were harvested by centrifugation
(3,000 × g, 30 min, 4°C). SARS-CoV NP levels in superna-Wang et al. Virology Journal 2010, 7:99
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tants were determined by Western blotting using anti-
SARS-CoV NP horse polyclonal IgG as the primary anti-
body.
SARS-CoV NP was purified by affinity chromatography
using His. Bind® Resin (Novagen) and ion exchange chro-
matography, using the Econo pac High CM cartridge
(Bio-Rad). Purified NP was desalted using a PD-10 desalt-
ing column (Amersham) and concentrated by ultrafiltra-
tion using Centricon™ centrifugal filters (10 kDa MWCO,
Millipore). Purified NP was suspended in HBS-EP buffer
(pH 7.4, appropriate for BIAcore). SARS-CoV NP con-
centration was determined using a BCA protein assay
reagent kit (Pierce). SARS-CoV NP activity was detected
by indirect ELISA with anti-SARS-CoV NP horse poly-
clonal antibody.
Identification of SARS-CoV NP-binding host cellular 
proteins
2BS cells were washed twice in cold 1× PBS and har-
vested. Pellets were lysed in 700 μL lysis buffer (1% Non-
idet P40 and 20 μL protease inhibitor cocktail set III
(Calbiochem) in 1 mL HBS-EP Buffer (pH 7.4, BIAcore),
followed by freezing at -70°C and thawing at room tem-
perature three times. Cells were harvested by centrifuga-
tion (12,000 × g, 20 min, 4°C). Supernatant was collected,
aliquoted, and stored at -70°C.
Host cell protein capturing was performed on a Sensor
Chip CM5 (Amersham Bioscience) using BIAcore3000
and the amine coupling direct capture method, as
described by the manufacturer. Briefly, SARS-CoV NP
was diluted in 10 mM NaAc (pH 5.5). A Sensor Chip
CM5 flow cell was activated with 70 μL of a mixture of
EDC/NHS (Amine Coupling Kit, Amersham Bioscience),
SARS-CoV NP (70 μL, 80 μg/mL) injected, and the flow
cell was blocked using ethanolamine (70 μL, 1 M). Host
cell lysate was then injected and allowed to flow through
the cell containing immobilized SARS-CoV NP. A flow
cell immobilized with HBS-EP buffer through which an
identical volume of host cell lysate flowed represented the
n e g a t i v e  c o n t r o l .  L y s i s  b u f f e r ,  i n j e c t e d  i n t o  a  f l o w  c e l l
immobilized with SARS-CoV NP, functioned as the blank
c o n t r o l .  T h e  r e a c t i o n  u n i t  ( R U )  o f  S A R S - C o V  N P  i s
obtained thus: RUreaction - RUblank control - RUnegative control =
RUSARS-CoV NP
Captured proteins were precipitated by addition of a
three-fold volume of cold acetone at -20°C overnight. Pel-
lets were dissolved in HBS-EP buffer (10 μL) and 2× load-
ing buffer (10 μL) and then resolved by 1-D SDS-PAGE
on a 12% gel. The gel was stained using modified
Neuhoff's colloidal Coomassie blue G-250 stain solution
(0.12% (w/v) Coomassie Blue G-250 dye, 10% (w/v)
ammonium sulfate, 10% (v/v) phosphoric acid, 20% (v/v)
methanol) [12].
Protein bands of interest were cut out of the gel and
rinsed twice in 50% (v/v) methanol (HPLC grade). In-gel
digestion was performed using sequencing-grade modi-
fied trypsin (Promega). Extracted peptides were analyzed
by matrix-assisted laser desorption ionization time-of-
flight (MALDI-TOF) mass spectrometry by the Life Sci-
ence Academy of Beijing University, China using an
Ultraflex™ MALDI-TOF/TOF (Bruker) and Data Explorer
(v. 4.0). Proteins were identified by comparison of their
monoisotopic masses with those in the NCBI nonredun-
dant or SwissProt databases using the MS-Fit search
engine of ProteinProspector.
Pulldown assay
E. coli BL21 were transformed with the pGEX-5X-1-p42
plasmid. The fusion protein p42-GST was expressed by
addition of IPTG (1 mM) at 22°C for 12 h. E. coli were
lysed in lysis buffer (20 mM Tris-HCl (pH 8.0), 200 mM
NaCl, 1 mM EDTA (pH 8.0), 0.5% NP40). SDS-PAGE and
immunoblotting (anti-GST mAb, Pharmacia) were used
to identify soluble expression of the p42-GST fusion pro-
tein.
Glutathione Sepharose 4B beads (Pharmacia, GE) were
suspended in lysis buffer to a concentration of 50% (w/v).
Lysates of E. coli expressing the p42-GST fusion protein
(1 mL), lysates of E. coli expressing GST alone, and lysis
buffer represented the test sample, negative control, and
blank control, respectively. Glutathione Sepharose 4B
beads and bacterial lysates were added into three tubes,
mixed for 60 min at 4°C, and 40 μL of this mixture was
saved for SDS-PAGE analysis. The remaining mixture
was washed with lysis buffer three times. Pellets were sus-
pended in lysis buffer (200 μL), to which was added puri-
fied SARS-CoV NP (100 μL) and the mixture was further
incubated at 4°C. After 3 h, the reaction mixture was
washed three times in cold lysis buffer and eluted by boil-
ing in 2× loading buffer. Eluted materials were subse-
quently analyzed by immunoblotting.
Immunofluorescent (IF) assay
2BS cells were cultured on coverslips in 6-well plates to
70-80% confluence and transfected with plasmid
pcDNA3.0-SNP22b using the lipofectAMINE™ 2000
transfection kit (Invitrogen). At 48 h after transfection,
coverslips were washed in 1× PBS and fixed in 1% para-
formaldehyde. Coverslips were then blocked with 5% (w/
v) skimmed milk at 37°C for 60 min and washed six times
in 1× PBS. Following incubation with a 1:100 dilution of
mouse anti-SARS-CoV NP mAb and a 1:100 dilution of
anti-p42 polyclonal antibody (Biomol, USA) at 37°C for
60 min, coverslips were washed six times with 1× PBS.
After incubation with a 1:80 dilution of goat anti-rabbit
IgG-FITC (Sigma) and a 1:200 dilution of goat anti-
mouse IgG-TRITC (Sigma) conjugates at 37°C for 45 min,Wang et al. Virology Journal 2010, 7:99
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coverslips were again washed six times in distilled water
and air-dried before being mounted on a slide with inter-
spaces containing 50% (v/v) glycerol. Photomicrographs
were taken using a confocal microscope (Confocal
Microscope FluoView™ FV1000).
Results
Expression, identification and purification of SARS-CoV NP
A plasmid expression vector, pET22b-SNP22b, was con-
structed to express SARS-CoV NP in E.  coli  BL21.
Expression of SARS-CoV NP was confirmed by SDS-
PAGE (Fig. 1A) and Western blotting using a horse poly-
clonal antibody against SARS-CoV NP (Fig. 1B). When
expression was induced using isopropyl β-D-thiogalacto-
pyranoside (IPTG), cells transfected with pET22b-
SNP22b produced large amounts of SARS NP, amounting
to up to 2% of total soluble protein (Fig. 1A; lanes 4 and
8).
Purification of SARS-CoV NP was achieved first by
Ni2+ chelate affinity chromatography, where SARS-CoV
NP was eluted using wash buffer containing imidazole
(250 mM), and then further purified by cation exchange
chromatography. The purity of SARS-Co V NP achieved
by means of this procedure was greater than 90%. SARS-
CoV NP was desalted, dissolved in HBS-EP buffer, con-
centrated, and quantified. Indirect ELISA data suggested
that purified SARS-CoV NP had a specific antibody bind-
ing activity similar to the native form (data not shown).
Capture of proteasome subunit p42 by SARS-CoV NP
SARS-CoV NP was diluted to 140 μg/mL in 10 mM NaAc
(pH 5.5) for immobilization. Regeneration was achieved
using NaOH (50 mM). Immobilization of SARS-CoV NP
in a sensor chip CM5 flow cell resulted in an RU value of
12355.1. This increased to 31 after HBS-EP buffer was
immobilized in an adjacent flow cell of the same chip and
increased further upon addition of 2BS cell lysates to the
flow cell containing SARS-CoV NP. A stable level (1120
RU) was achieved after a total of 70 μL 2BS cell lysate was
injected. The flow cell was then washed six times and
NaOH (5 μL, 50 mM) was injected to elute proteins
bound to SARS-CoV NP. The RU values of the blank and
negative controls were 23 RU and 41 RU, respectively.
Thus, the specific reaction of SARS-CoV NP and 2BS cell
lysate was quantified as 1056 RU (calculated by 1120RU-
23RU-41RU), suggesting that SARS-CoV NP had bound
to at least one protein present in 2BS cell lysate (Fig. 2A).
Captured proteins were recovered and collected by
repeating the direct capture and blank control proce-
dures.
The protein(s) captured by SARS-CoV NP were precip-
itated, resolved by 1D SDS-PAGE and visualized using
modified Neuhoff's colloidal Coomassie blue G-250
staining. SARS-CoV NP was found to have bound three
proteins from 2BS cell lysate, the molecular weights of
which ranged from 43 to 66 kDa (Fig. 2B, lane 3). No pro-
tein was captured from the blank or negative controls
(Fig. 2B, lanes 1, 2). Analysis by MALID-TOF mass spec-
trometry identified the proteins as: 26S proteasome regu-
latory subunit S10B (proteasome subunit p42 or
proteasome 26S subunit ATPase 6, P62333; Fig. 2B),
cytokeratin 1 (CK1, P04264), and cytoskeletal protein 10
(CK10, P13645). Cytokeratins are a subfamily of interme-
diate filament proteins. Cytokertin 1 (CK1) has the high-
est molecular weight and the highest isoelectric point of
the family, while cytokeratin 10 has the lowest molecular
weight and a low isoelectric point. These proteins are
expressed in combinations that vary according to the type
of epithelium within which they are found. Proteasome
subunit p42 was selected for further assessment; the roles
of CK1 and CK10 will be considered in a subsequent
study.
Interaction of proteasome subunit p42 with SARS-CoV NP 
in vitro
To examine further the interaction between SARS-CoV
NP and proteasome subunit p42 in vitro, GST and the
p42-GST fusion protein were produced, purified, and
identified by 1D SDS-PAGE (Fig. 3A) and Western blot-
ting, using an anti-GST mAb (Fig. 3B). Interaction of
SARS-CoV NP with the proteasome subunit p42 in vitro
was identified using the p42-GST fusion protein pull-
down technique. Data suggested that the SARS-CoV NP
was pulled down by p42-GST fusion protein (Fig. 4, lanes
6, 8), but not by either of the negative controls: GST alone
(Fig. 4, lanes 1, 3, 5, 7) or glutathione Sepharose 4B beads
Figure 1 Expression and Identification of SNP22b (SARS-CoV NP). 
(A) Supernatants (lanes 1 and 10) and pellets (lanes 2 and 6) of E. coli 
BL21 containing the pET22b-SNP22b vector expressing SARS-CoV NP, 
without IPTG induction. Supernatants (lanes 3 and 7) and pellets (lanes 
4 and 8) of E. coli BL21 containing the pET22b-SNP22b vector and ex-
pressing SARS-CoV NP, induced with IPTG. Pellets of E. coli BL21 con-
taining pET22b induced with IPTG (lane 5). Molecular weight markers 
(lane 9). The position of SARS-CoV NP (~47 kDa) is indicated by an ar-
row. (B) Western blot analysis of SARS-CoV NP using an anti-SARS-CoV 
NP horse polyclonal antibody. Lysate of E. coli BL21 expressing SARS-
CoV NP, induced by IPTG (lane 1). Lysate of E. coli BL21 containing 
pET22b induced by IPTG (lane 2). Molecular weight markers (lane 3). 
The position of SARS-CoV NP (~47 kDa) is indicated by an arrow.Wang et al. Virology Journal 2010, 7:99
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(Fig. 4, lanes 2, 9). Thus, these data suggest that SARS-
CoV NP exhibits a specific interaction with the protea-
some subunit p42 in vitro.
Co-localization of SARS-CoV NP and proteasome subunit 
p42 in 2BS cells
To analyze the interaction of SARS-CoV NP and protea-
some subunit p42 within host cells, SARS-CoV NP was
expressed in 2BS cells and identified by indirect immuno-
fluorescence using an anti-SARS-CoV NP mAb (Fig. 5A).
After transfection of 2BS cells with SNP22b-pcDNA3.0,
the proteasome subunit p42 was detected by means of an
anti-p42 antibody and anti-rabbit IgG-FITC conjugate
(Fig. 5B, lane 1; excitation wavelength 488 nm). Expres-
sion of SARS-CoV NP in 2BS cells was confirmed using
an anti-SARS-CoV NP mAb and anti-mouse IgG-TRITC
conjugate (Fig. 5, lane 2; excitation wavelength 568 nm).
Thus, the co-localization signals (Fig. 5, lane 3; excitation
Figure 2 Identification of SARS-CoV NP-associated cellular protein(s). (A) Interaction of SARS-CoV NP with 2BS cell lysate proteins. The maximum 
reaction intensity was 1120 RU (manual injection). Baseline (a), injection of host cell lysate (b), RU value of flow cell after injection of host cell lysate 
(reactive amount = RUc-RUa) (c), eluted and recovered captured proteins (d), regeneration of flow cell (e). (B) Proteins captured from 2BS cell lysate 
(lane 1), blank controls (lane 2), and negative controls (lane 3). Molecular weight markers (lane 4). Arrows indicate the position of captured proteins.
Figure 3 Expression and identification of GST and the p42-GST 
fusion protein. (A) Lysate of E. coli BL21 containing the pGEX-5X-1-
p42 vector, expressing p42-GST fusion protein without IPTG induction 
(lanes 1, 5) or induced by IPTG (lanes 2, 4). Lysate of E. coli BL21 contain-
ing the pGEX-5X-1 vector expressing GST with IPTG induction (lane 6) 
or without IPTG (lane 7). Molecular weight markers (lane 3). (B) Western 
blot analysis of p42-GST fusion protein and GST expression using an 
anti-GST mAb. Lysates of GST-expressing E. coli BL21 with IPTG induc-
tion (lanes 1, 2). Lysates of p42-GST fusion protein-expressing E. coli 
BL21 with IPTG induction (lanes 6, 7). Supernatants of E. coli BL21 ex-
pressing GST lysed using lysozyme (lane 3). Supernatants of E. coli BL21 
expressing p42-GST fusion protein lysed by lysozyme (lane 5). Molecu-
lar weight markers (lane 4).
Figure 4 Western blot analysis of the interaction between p42-
GST fusion protein and SARS-CoV NP in vitro. Bead + lysis buffer + 
NP (lane 1), bead + lysis buffer (lane 2), bead + GST lysate + NP (lane 3), 
bead + GST lysate (lane 4). Molecular weight markers (lane 5). SARS-
CoV NP-SNP22b (positive control; lane 6), bead + p42-GST lysate (lane 
7), bead + p42-GST lysate + NP (lane 8), p42-GST fusion protein bacte-
rial lysate (lane 9). The position of SARS-CoV NP is indicated by an ar-
row.
SARS-CoV NPWang et al. Virology Journal 2010, 7:99
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by both 488 nm and 568 nm) of p42 and SARS-CoV NP in
2BS cells were elucidated by merging lane 1 and lane 2 of
Fig 4. This usually occurs when fluorescently labeled mol-
ecules bind to targets in close proximity.
Discussion
SARS is an emerging infectious disease that has become a
global public health concern in the 21st century. However,
the pathogenesis of SARS remains unclear. It has been
suggested that the cytokine storm observed during the
early stages of SARS in most patients contributes to the
progression of systemic inflammatory response syn-
drome [13]. The SARS-CoV NP has been shown to be
highly immunogenic and the predominant target for the
humoral immune response during infection with SARS-
CoV [14]. This process may trigger cytokine production
and so induce apoptosis in host cells [13].
Law suggested that SARS-CoV, during infection of den-
dritic cells, evades the immune response by down-regu-
lating expression of the anti-viral chemokines IFN-α, β
and γ and IL-12p40, while simultaneously up-regulating
that of others: for example, TNF-α, IL-6, MIP-1α, and IP-
10 [15]. Additionally, it seems likely that proinflammatory
cytokines released by macrophages in pulmonary alveoli
play an important role in the pathogenesis of SARS.
SARS-CoV is capable of inducing apoptosis of Vero E6
cells in vitro [16]. Apoptosis of T- and B-lymphocytes in
the immune organs and pulmonary alveoli and mononu-
clear inflammatory infiltration in the lungs, lymph nodes,
and spleens of SARS-CoV infected individuals has been
observed. Some SARS-CoV proteins, for example, E pro-
tein, NP, ORF7a, ORF3a, and ORF3b, have been shown to
induce apoptosis in vitro [13,17-19]. Thus, the rapid
apoptosis induced by SARS-CoV may be one of the
mechanisms responsible for the damage to the lungs and
immune organs observed in SARS patients.
Interaction of viral and host proteins may contribute to
the processes involved in viral infection, replication, and
assembly and so increasing our knowledge of these inter-
actions may lead to increased insight into the pathology,
clinical manifestations, and pathogenesis of SARS. Li et
al. reported in 2003 that angiotensin-converting enzyme
2 acted as a functional receptor for the SARS-CoV by
binding to SARS-CoV S protein [20]. To further examine
the role of such interactions in the pathogenesis of SARS-
CoV infection, we investigated the ability of SARS-CoV
nucleocapsid protein to bind to host cell proteins. The
prokaryotic expression vector pET22b was used for solu-
ble expression of SARS-CoV NP. This vector contains the
PeIB signal peptide to assure correct conformation of NP
in E. coli. Because the SARS-CoV NP, unlike other SARS-
CoV proteins, contains no glycosylation site, the recombi-
nant form shows identical immune reactivity to that of
the native protein [21].
Data suggested that the proteasome subunit p42 of 2BS
cells interacted with SARS-CoV NP. To our knowledge,
this is the first report of such an interaction. Proteasome
subunit p42 (also called the 26S protease regulatory sub-
unit S10B) is a subunit of PA700 in the ubiquitin-protea-
some pathway (UPP). This pathway is one of a number of
intracellular proteolytic systems in eukaryotes and medi-
ates ATP-dependent degradation of ubiquitinated pro-
teins. The 26S ATP-dependent proteasome, formed from
the 20S proteasome and 19S regulatory particle (PA700),
is a multi-protein complex. The 20S component has pro-
teolytic activity, while the PA700 component binds ubiq-
uitinated proteins and promotes their degradation by the
20S component. Consistent with its ATPase activity, the
proteasome subunit p42 contains an ATP binding region
in a conserved 200 aa domain. The proteasome subunit
p42, together with the five other subunits, TBP1, MSS1,
S4, p45, and TBP7, assemble to form the PA700 compo-
nent. 26S proteasomes are distributed in the cytoplasm
and nucleolus [22,23]. The ubiquitin-proteasome path-
way mediates turnover of intracellular proteins. It plays a
central role in the degradation of short-lived and regula-
tory proteins that are themselves vital for correct func-
tioning of a variety of basic cellular processes including
regulation of the cell cycle, modulation of cell surface
receptor and ion channel expression, and antigen pro-
cessing and presentation [24].
While proteasomes do hydrolyze endogenous proteins,
they are also capable of degrading exogenous proteins: for
Figure 5 Co-localization of SARS-CoV NP and p42 in 2BS cells. (A) 
SARS-CoV NP was expressed in 2BS cells transfected with recombinant 
-pcDNA3.0+SNP22b (left panel), 2BS cells transfected with pcDNA3.0 
(right panel; negative control). (B) Proteasome subunit p42 in 2BS cells 
localized with anti-p42 antibody and anti-rabbit IgG-FITC conjugate, 
excitation at 488 nm (lane 1). SARS-CoV NP expressed in 2BS cells, lo-
calized using an anti-SARS-CoV NP mAb and anti-mouse IgG-TRITC 
conjugate, excitation at 568 nm (lane 2). Co-localization was detected 
by merging lanes 1 and 2 (lane 3).
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example, viral peptides. In this way, these complexes are
involved in defenses against viral infection. Interactions
between viruses and UPP have recently been reported.
Hepatitis B virus X protein (HBX) has been demonstrated
to target the proteasome complex after viral entry into
the cell [25]. Hu revealed that HBX is both a substrate and
a potential inhibitor of the proteasome complex. The
authors suggested that HBX may inhibit proteasome-
mediated proteolysis by binding two subunits (Sub4,
Sub7) of the 26S proteasome [26]. HBX expression inhib-
ited turnover of c-Jun and ubiquitin- arginine-β-galacto-
sidase, both known substrates of UPP [27]. HIV1 Tat
protein was shown to inhibit the degradative activity of
20S proteasomes, by interacting with the S6a subunit of
the 26S component [28]. Adenovirus E1A protein
enhanced degradation of topoisomerase II alpha protein,
via interaction with the S8 subunit of the 26S component
[29].
Evidence to date suggests that viruses employ two strat-
egies for proteasome inhibition; first, interference with
the antigen presentation activity of the proteasome, thus
promoting immune evasion. Second, stimulation of the
degradative activity of the 26S proteasome causes an
acceleration of G1/S turnover, thus promoting viral repli-
cation by interference with the cell cycle [30]. During
viral infection, UPP hydrolyzes viral proteins into short
peptides, which are then presented to CTL via MHC-1.
Activated CTL then attack virally infected cells. The tran-
scription factor nuclear factor-κB (NF-κB) is involved in
regulation of immunity and inflammation; the UPP plays
a central role in the regulation of NF-κB activation. When
a cell is infected by a virus, IκB is phosphorylated and
hydrolyzed by UPP, thus releasing NF-κB, which enters
the nucleus and activates transcription of genes encoding
inflammatory responses [31]. Thus, the UPP may play a
vital role in infection, and the host response to infection,
by a variety of viral pathogens. Development of a specific
inhibitor of UPP may have potential not only as an antivi-
ral, but also as an anti-tumor and anti-inflammatory
agent. Study of the interactions of components of the
UPP with viral proteins may provide useful information
relating to the pathogenesis of a number of diseases [32].
Determining potential mechanisms of the interaction
of SARS-CoV NP with proteasome subunit p42 was out-
side the scope of this study. However, such information
may enhance our understanding of the activities of pro-
teasomes in eukaryotic cells. We assumed that the inter-
action between SARS-CoV NP and proteasome subunit
p42 inhibited the proteolytic activity of proteasomes. The
actions of SARS-CoV NP and some other viral proteins
may act to increase the deleterious effect of SARS-CoV
infection, resulting in increased permeability, inflamma-
tory infiltration, and mononuclear cell soakage, perhaps
even accelerating pulmonary fibrosis. Moreover, this
interaction may impair proteolysis of viral proteins and
their presentation to CTLs and thus aid SARS-CoV eva-
sion of immune effectors. Furthermore, such activity may
affect inflammatory processes, resulting in the immunop-
athological damage so common in SARS. SARS-CoV NP
is post-translationally modified by covalent attachment to
small ubiquitin-like modifiers. Sumoylation of NP aids in
promoting homo-oligomerization and assists in interfer-
ence with host cell division [33].
Whether SARS-CoV NP interacts with proteasome
subunit p42 in vivo remains unknown, and so further
studies are required to fully determine the nature of this
interaction and its effect in vivo during SARS-CoV infec-
tion. Furthermore, more research on the downstream
effect of this interaction may lead to the development of
novel antiviral agents effective against this debilitating
and often fatal infection.
Conclusions
In this study, we demonstrated for the first time that
SARS-CoV NP interacts with the proteasome subunit p42
in vitro. This finding may lead to a new direction in
research focusing on the molecular mechanisms of
SARS-CoV infection and the pathogenesis of SARS.
Whether the interaction of SARS-CoV NP and p42
impacts presentation of viral antigens and assists in viral
evasion of CTLs and/or promotes enhanced inflamma-
tory responses resulting in immunopathological damage
remain to be determined.
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